Europe Alpha-Glucosidase Inhibitors Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | 2.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Alpha-Glucosidase Inhibitors Market Analysis
The Europe Alpha-Glucosidase Inhibitors Market size is expected to reach USD 1 billion over the forecast year, growing at a CAGR of 2.20% during the forecast period.
The COVID-19 epidemic has had a significant effect on the market for insulin drugs and devices. Patients with type-1 diabetes are more affected by COVID-19. Since people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the manufacturers of insulin drugs worked with local governments to provide insulin drugs to diabetes patients.
NovoNordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin drugs.
The rates of newly diagnosed Type 1 and Type 2 diabetes cases are seen increasing among the youth in Europe. The prevalence of diabetes among all ages in the European region is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. The prevalence of autoimmune Type 1 diabetes is also increasing in Europe, and as per sources, Europe has the highest number of children with Type 1 diabetes. Though Type 2 patients are initiated with oral drugs, insulin may also be required when glucose levels are not well controlled due to an unhealthy lifestyle. Thus, the demand for insulin also exists among Type 2 diabetes patients.
The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Europe are indications of the increasing usage of diabetic drug products. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Europe Alpha-Glucosidase Inhibitors Market Trends
Rising Diabetes Prevalence in Europe Region
Due to the increased prevalence of diabetes, European nations are burdened with significant healthcare costs. In diabetes care, devices for safer and more precise insulin delivery technological developments increased over time. Medtronic released the first integrated smart insulin pen. With the help of the Medtronic Integrated Insulin Pen, patients may control their blood sugar levels by receiving real-time glucose readings and information about their insulin dosage. The European countries are suffering from the burden of high diabetes expenditure. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to other statistics from IDF, every year, 21,600 children are added to the type-1 diabetic population pool. These figures indicate that approximately 9% of the total healthcare expenditure is spent on diabetes in Europe. For patients relying on insulin pumps or multiple daily injections (MDI) therapy, the CGMs are an effective tool that helps improve glycemic balance without aggregating the danger of severe hypoglycemia.
Better diabetes control is a goal shared by the government and businesses. For instance, the National Service Framework (NSF) program raises service quality and addresses care disparities by establishing national standards. The German Diabetes Society is one of the largest medical-scientific societies in Germany. The organization supports the research and training of medical personnel and develops medical guidelines for the diagnosis of diabetes.
The market will probably rise in the future due to the rising incidence of obesity, expanding genetic risk factors for type-2 diabetes, and the causes mentioned above.
France is Expected to Dominate the Europe Alpha-Glucosidase Inhibitors Market.
Although alpha-glucosidase inhibitors are studied as monotherapy and as part of a combination regimen for treating diabetes, they are not considered standard first-line therapy due to their low efficacy and poor tolerance. If the gastrointestinal side effects are tolerated, they may play a role in a combination regimen in people who consume high-carbohydrate diets and include high postprandial glucose levels.
The alpha-glucosidase inhibitors (acarbose, miglitol, and voglibose) are extensively studied in France. Two of them, acarbose and miglitol, are commercially available in the United States and France. They inhibit upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides in a dose-dependent manner when taken orally. As a result, these drugs slow dietary carbohydrate absorption. The slower rise in postprandial blood glucose concentrations may benefit both type 1 and type 2 diabetes. Acarbose may also increase insulin sensitivity in older patients with type 2 diabetes, though this may be a nonspecific effect associated with improved glycemia. When used alone or combined with other agents that do not cause hypoglycemia, alpha-glucosidase inhibitors do not cause hypoglycemia.
The market is expected to grow during the forecast period due to the factors above.
Europe Alpha-Glucosidase Inhibitors Industry Overview
The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in Europe.
Europe Alpha-Glucosidase Inhibitors Market Leaders
-
Takeda
-
Pfizer
-
Bayer
-
Sun Pharma
-
Glenmark
*Disclaimer: Major Players sorted in no particular order
Europe Alpha-Glucosidase Inhibitors Market News
- April 2023: A study was planned to move towards drug repurposing by utilizing Food and drug administration (FDA)-approved drugs against α-glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing to remove clashes to find the potential inhibitor against α-glucosidase.
- July 2022: The Indian Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) fixed the prices of 84 drug formulations, including those used to treat diabetes.
Europe Alpha-Glucosidase Inhibitors Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Drug
5.1.1 Alpha-glucosidase Inhibitors
5.2 Geography
5.2.1 Germany
5.2.2 Spain
5.2.3 Italy
5.2.4 France
5.2.5 United Kingdom
5.2.6 Russia
5.2.7 Rest of Europe
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Bayer pharma
7.1.2 Takeda
7.1.3 Pfizer
7.1.4 Glenmark pharma
7.1.5 Sun pharma
7.1.6 Torrent
7.1.7 Unichem
7.1.8 Hexalag
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Europe Alpha-Glucosidase Inhibitors Industry Segmentation
Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. By competitive inhibition, they block enzymes that convert complicated non-absorbable carbs into simple, absorbable carbohydrates. Glucoamylase, sucrase, maltase, and isomaltase are some of these enzymes. Europe Alpha-Glucosidase Inhibitors Market is segmented by geography (Germany, Spain, Italy, France, United Kingdom, Russia, and the rest of Europe). The report offers the value (in USD) and Volume (in units) for the above segments.
| Drug | |
| Alpha-glucosidase Inhibitors |
| Geography | |
| Germany | |
| Spain | |
| Italy | |
| France | |
| United Kingdom | |
| Russia | |
| Rest of Europe |
Europe Alpha-Glucosidase Inhibitors Market Research FAQs
What is the current Europe Alpha-Glucosidase Inhibitors Market size?
The Europe Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 2.20% during the forecast period (2024-2029)
Who are the key players in Europe Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, Sun Pharma and Glenmark are the major companies operating in the Europe Alpha-Glucosidase Inhibitors Market.
What years does this Europe Alpha-Glucosidase Inhibitors Market cover?
The report covers the Europe Alpha-Glucosidase Inhibitors Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Alpha-Glucosidase Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Alpha-Glucosidase Inhibitors Industry Report
Statistics for the 2024 Europe Alpha-Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Alpha-Glucosidase Inhibitors analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Europe Alpha-Glucosidase Inhibitors Market Report Snapshots
